Related Experiment Video
Updated: Feb 9, 2026

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS
Published on: August 10, 2017
Growth Suppression of Glioma Cells Using HDAC6 Inhibitor, Tubacin
1Department of Neurosurgery, Shandong Province Third Hospital, Jinan, Shandong, China.
Abstract:
In cancer research, autophagy has been revealed as one of the major ways to maintain the metabolism of cancer cells, including glioma cells, through protein degradation. Meanwhile, autophagy is also regarded as a kind of mechanism to protect glioma cells from a harmful stimulus, such as chemical and radiation treatment. So, the inhibition of autophagy may be very helpful in curing glioma. This study aimed to determine the effect of autophagic inhibition on glioma cells using tubacin, a specific inhibitor of histone deacetylase 6(HDAC6). According to the results, tubacin inhibited the growth of both U251 and LN229 cells, which was accompanied by lower HDAC6 activity and accumulated autophagosome. The inhibition of HDCA6 also led to accumulation of autophagosome and death of glioma cells. Moreover, the combined treatment of tubacin and temozolomide, an alkylating agent used to treat glioblastoma, induced more severe glioma cell death. Thus, it can be concluded that inhibition of HDAC6 suppressed growth and drug resistance of glioma cells in-vitro through autophagic suppression and blocking of fusion of autophagosome and lysosome.
Insights
Inhibiting histone deacetylase 6 (HDAC6) with tubacin suppressed glioma cell growth and drug resistance by blocking autophagy. This approach, combined with temozolomide, enhanced glioma cell death, offering a potential therapeutic strategy.
Area of Science:
- Oncology
- Cell Biology
- Biochemistry
Background:
- Autophagy is crucial for cancer cell metabolism and survival, particularly in glioma.
- Autophagy acts as a protective mechanism for glioma cells against treatments like chemotherapy and radiation.
- Targeting autophagy presents a potential strategy for glioma treatment.
Purpose of the Study:
- To investigate the effect of inhibiting histone deacetylase 6 (HDAC6) on glioma cells.
- To evaluate the role of tubacin, an HDAC6 inhibitor, in modulating autophagy and glioma cell viability.
- To assess the combined effect of tubacin and temozolomide on glioma cell death.
Main Methods:
- Utilized tubacin, a specific inhibitor of HDAC6.
- Assessed the impact of tubacin on U251 and LN229 glioma cell lines.
- Measured HDAC6 activity, autophagosome accumulation, and cell death.
- Evaluated the combined efficacy of tubacin and temozolomide.
Main Results:
- Tubacin inhibited the growth of U251 and LN229 glioma cells.
- Tubacin treatment led to decreased HDAC6 activity and increased autophagosome accumulation.
- HDAC6 inhibition resulted in autophagosome accumulation and glioma cell death.
- Combined treatment with tubacin and temozolomide significantly increased glioma cell death.
Conclusions:
- Inhibition of HDAC6 suppresses glioma cell growth and enhances drug sensitivity in vitro.
- Autophagic suppression and impaired autophagosome-lysosome fusion are key mechanisms.
- Targeting HDAC6-mediated autophagy offers a promising therapeutic avenue for glioma treatment.
More Related Videos
Related Concept Videos
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Cells Coordinate Growth and Proliferation
Population Growth
Meristems and Plant Growth
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids
However, this neutralization reaction between...

